list of fda approved glp-1 receptor agonists Pharmacovigilance Assessment Compounded Agonists: Insights From the Adverse Event Reporting System How Employers Can Optimize Benefits
Description
Clinical data suggests Wegovy causes slightly lower rates of gastrointestinal side effects compared to Zepbound

The law (Medicare Modernization Act of 2003) explicitly excludes drugs when used for weight loss, weight gain, or anorexia. (ASPE) Some proposed changes (including reinterpreting the exclusion for obesity) were considered , but in April 2025 those were not finalized

88 , 89 Common reasons include gastrointestinal side effects, injection burden, high cost, and limited insurance coverage

Institutional demand accounted for 52% of 2025 revenue in Germany

302,303,304,305 GLP-1R signaling, through PKA, inhibits this process, possibly by promoting IB stability or inhibiting its phosphorylation, thus reducing NF-B activation and nuclear translocation
